Safety & Efficacy of Peg-ASP-based CCRT in Early Stage ENKTL
NCT06406556
·
clinicaltrials.gov ↗
PHASE2
Phase
RECRUITING
Status
90
Enrollment
OTHER
Sponsor class
Conditions
Extranodal NK/T-cell Lymphoma
Interventions
COMBINATION_PRODUCT:
Pegaspargase combined with concurrent radiotherapy.
Sponsor
Sun Yat-sen University